ARTHEx Biotech Delivers Multiple Presentations at IDMC-15 Highlighting Clinical Progress of ATX-01 and Mechanistic Insights for Myotonic Dystrophy Type 1 (DM1) and 2 (DM2)

VALENCIA, Spain, May 27, 2026 /PRNewswire/ -- ARTHEx Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced multiple presentations at the 15th International Myotonic Dystrophy Consortium (IDMC-15) meeting, taking place...